Please provide your email address to receive an email when new articles are posted on . Patients who develop PTSD after MI are more prone to stress-induced myocardial ischemia than patients who did ...

Among patients with diabetes and without known coronary artery disease and referred for myocardial perfusion imaging, 12.7% had significant ischemia, and 60% had reduced myocardial blood flow reserve ...

High-dose therapy followed by autologous stem cell transplantation is a standard treatment for refractory or relapsed high-grade lymphomas. Several conditioning regimen have been employed, BEAM being ...

In the CIAO ancillary study of patients who were screened for the ISCHEMIA trials but were excluded because they had ischemia but no obstructive CAD, stress echocardiography results and angina ...

Since the Apple Watch added the ECG app with the Series 4, numerous stories have surfaced about how the app has contributed to saving people’s lives. Now, a new article from the European Heart Journal ...

Until the early 20th century, the human life expectancy was less than 50 years, and infections were often fatal. Only in the past century have humans, on average, lived long enough for cardiovascular ...

Ischemia is a condition in which there is insufficient blood flow to a part of the body. It is often caused by plaque building up and thickening or hardening the artery supplying that area or organ.

PARIS — New findings from the controversial ORBITA trial provide a lift for percutaneous coronary intervention (PCI) in stable angina but also mixed results for the predictive power of fractional flow ...

Long-chain fatty acid uptake, which provides a large part of myocardial energy, is impaired in human and murine hearts deficient in the membrane fatty acid translocase, FAT/CD36. We examined ...

In patients with ischemic heart disease, myocardial ischemia–reperfusion injury (IRI) can aggravate their condition even worse, and diabetes increases their risk of myocardial IRI. Pathological ...

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ...